Concepts (279)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Nicotinic | 8 | 2013 | 154 | 1.640 |
Why?
|
| Models, Chemical | 4 | 2006 | 86 | 1.060 |
Why?
|
| Adipose Tissue | 15 | 2018 | 465 | 0.860 |
Why?
|
| Stilbenes | 3 | 2017 | 35 | 0.790 |
Why?
|
| Models, Molecular | 6 | 2013 | 1070 | 0.760 |
Why?
|
| Membrane Potentials | 3 | 2006 | 304 | 0.730 |
Why?
|
| Cell Membrane | 3 | 2006 | 459 | 0.680 |
Why?
|
| Muscle, Skeletal | 9 | 2021 | 937 | 0.610 |
Why?
|
| Insulin Resistance | 8 | 2018 | 639 | 0.590 |
Why?
|
| Ion Channel Gating | 2 | 2006 | 123 | 0.510 |
Why?
|
| Antioxidants | 2 | 2017 | 337 | 0.500 |
Why?
|
| Nicotinic Agonists | 2 | 2006 | 44 | 0.470 |
Why?
|
| Metabolic Syndrome | 2 | 2017 | 329 | 0.460 |
Why?
|
| Torpedo | 4 | 2013 | 37 | 0.390 |
Why?
|
| Computer Simulation | 4 | 2006 | 637 | 0.380 |
Why?
|
| Acetylcholine | 2 | 2013 | 82 | 0.370 |
Why?
|
| Binding Sites | 7 | 2013 | 1292 | 0.340 |
Why?
|
| Obesity | 7 | 2018 | 2227 | 0.300 |
Why?
|
| Static Electricity | 5 | 2006 | 40 | 0.300 |
Why?
|
| Prenatal Exposure Delayed Effects | 3 | 2019 | 226 | 0.280 |
Why?
|
| Tubocurarine | 2 | 2006 | 4 | 0.270 |
Why?
|
| Human Growth Hormone | 2 | 2018 | 74 | 0.270 |
Why?
|
| Acetylcholinesterase | 1 | 2006 | 20 | 0.270 |
Why?
|
| Conotoxins | 2 | 2006 | 3 | 0.260 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2016 | 1225 | 0.260 |
Why?
|
| Intra-Abdominal Fat | 2 | 2017 | 51 | 0.240 |
Why?
|
| Protein Binding | 8 | 2013 | 1743 | 0.230 |
Why?
|
| Liver | 4 | 2017 | 1735 | 0.220 |
Why?
|
| Glucose | 3 | 2018 | 865 | 0.220 |
Why?
|
| Fluorescence Resonance Energy Transfer | 4 | 2008 | 63 | 0.210 |
Why?
|
| Insulin | 3 | 2017 | 1197 | 0.210 |
Why?
|
| Thinness | 2 | 2016 | 68 | 0.200 |
Why?
|
| Interleukin-6 | 3 | 2017 | 393 | 0.200 |
Why?
|
| Triglycerides | 5 | 2017 | 562 | 0.200 |
Why?
|
| Software | 1 | 2006 | 677 | 0.200 |
Why?
|
| Models, Biological | 1 | 2006 | 1442 | 0.190 |
Why?
|
| Rats, Wistar | 9 | 2016 | 359 | 0.190 |
Why?
|
| Satellite Cells, Skeletal Muscle | 1 | 2021 | 31 | 0.190 |
Why?
|
| Glucocorticoids | 2 | 2003 | 379 | 0.190 |
Why?
|
| Absorptiometry, Photon | 3 | 2017 | 178 | 0.190 |
Why?
|
| Calmodulin | 3 | 2009 | 228 | 0.190 |
Why?
|
| Inflammation | 4 | 2017 | 1402 | 0.180 |
Why?
|
| Progesterone | 1 | 2003 | 624 | 0.180 |
Why?
|
| Optic Atrophies, Hereditary | 1 | 2020 | 16 | 0.170 |
Why?
|
| Cholesterol | 4 | 2017 | 525 | 0.170 |
Why?
|
| COUP Transcription Factor I | 1 | 2020 | 91 | 0.170 |
Why?
|
| Body Composition | 3 | 2017 | 513 | 0.170 |
Why?
|
| Animals | 24 | 2020 | 33728 | 0.170 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2017 | 514 | 0.160 |
Why?
|
| Blotting, Western | 3 | 2017 | 1101 | 0.160 |
Why?
|
| Maternal Exposure | 1 | 2019 | 148 | 0.150 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2017 | 288 | 0.150 |
Why?
|
| Diet, High-Fat | 2 | 2017 | 208 | 0.150 |
Why?
|
| Blood Glucose | 3 | 2017 | 1114 | 0.150 |
Why?
|
| TRPV Cation Channels | 1 | 2017 | 35 | 0.150 |
Why?
|
| Cranial Irradiation | 1 | 2018 | 69 | 0.150 |
Why?
|
| Memory Disorders | 1 | 2020 | 235 | 0.150 |
Why?
|
| Neuronal Plasticity | 1 | 2020 | 274 | 0.140 |
Why?
|
| Fructosamine | 1 | 2017 | 6 | 0.140 |
Why?
|
| Hippocampus | 2 | 2020 | 812 | 0.140 |
Why?
|
| Hypothermia | 1 | 2017 | 54 | 0.140 |
Why?
|
| Biopsy | 1 | 2021 | 1239 | 0.140 |
Why?
|
| Quadriceps Muscle | 1 | 2017 | 12 | 0.140 |
Why?
|
| White Matter | 1 | 2019 | 181 | 0.140 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2017 | 22 | 0.140 |
Why?
|
| Fasting | 1 | 2018 | 296 | 0.140 |
Why?
|
| Physical Conditioning, Animal | 1 | 2018 | 91 | 0.140 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2018 | 340 | 0.140 |
Why?
|
| Leptin | 2 | 2017 | 211 | 0.140 |
Why?
|
| Calcium Channels, L-Type | 2 | 2009 | 53 | 0.130 |
Why?
|
| Porosity | 2 | 2006 | 39 | 0.130 |
Why?
|
| Neurogenesis | 1 | 2018 | 196 | 0.130 |
Why?
|
| Spectrometry, Fluorescence | 3 | 2006 | 87 | 0.130 |
Why?
|
| Fetal Development | 1 | 2017 | 111 | 0.130 |
Why?
|
| Disease Models, Animal | 5 | 2018 | 4269 | 0.130 |
Why?
|
| Weight Gain | 2 | 2017 | 401 | 0.130 |
Why?
|
| Cholesterol, HDL | 1 | 2017 | 348 | 0.130 |
Why?
|
| Recovery of Function | 1 | 2017 | 437 | 0.120 |
Why?
|
| Double-Blind Method | 2 | 2017 | 1588 | 0.120 |
Why?
|
| Vitamins | 1 | 2015 | 107 | 0.120 |
Why?
|
| Brain Ischemia | 1 | 2017 | 251 | 0.120 |
Why?
|
| Glucose Intolerance | 1 | 2016 | 75 | 0.120 |
Why?
|
| Peptides | 3 | 2009 | 796 | 0.120 |
Why?
|
| Diet, Protein-Restricted | 1 | 2016 | 82 | 0.120 |
Why?
|
| Vitamin D Deficiency | 1 | 2015 | 70 | 0.120 |
Why?
|
| Stress, Psychological | 1 | 2019 | 557 | 0.120 |
Why?
|
| Glucose Transporter Type 4 | 2 | 2011 | 20 | 0.120 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 406 | 0.120 |
Why?
|
| Rats | 8 | 2018 | 3631 | 0.120 |
Why?
|
| Kinetics | 2 | 2006 | 1313 | 0.110 |
Why?
|
| Lipopolysaccharides | 1 | 2016 | 291 | 0.110 |
Why?
|
| Vitamin D | 1 | 2015 | 157 | 0.110 |
Why?
|
| Mutagenesis, Site-Directed | 3 | 2009 | 317 | 0.110 |
Why?
|
| Quaternary Ammonium Compounds | 2 | 2006 | 27 | 0.110 |
Why?
|
| Male | 19 | 2020 | 60040 | 0.110 |
Why?
|
| Blood Pressure | 2 | 2017 | 1315 | 0.110 |
Why?
|
| Cognition Disorders | 1 | 2018 | 554 | 0.110 |
Why?
|
| Cell Differentiation | 1 | 2021 | 1915 | 0.110 |
Why?
|
| Cholesterol, LDL | 1 | 2017 | 557 | 0.110 |
Why?
|
| Nerve Tissue Proteins | 1 | 2019 | 1116 | 0.110 |
Why?
|
| Eating | 2 | 2008 | 373 | 0.110 |
Why?
|
| Calcium | 3 | 2009 | 1095 | 0.110 |
Why?
|
| Postprandial Period | 1 | 2013 | 77 | 0.110 |
Why?
|
| Structure-Activity Relationship | 2 | 2006 | 568 | 0.100 |
Why?
|
| Meals | 1 | 2013 | 56 | 0.100 |
Why?
|
| Dietary Supplements | 2 | 2015 | 471 | 0.100 |
Why?
|
| Diffusion Tensor Imaging | 3 | 2019 | 239 | 0.100 |
Why?
|
| RNA, Messenger | 7 | 2012 | 2817 | 0.100 |
Why?
|
| Sweetening Agents | 1 | 2011 | 29 | 0.100 |
Why?
|
| Dexamethasone | 3 | 2003 | 272 | 0.100 |
Why?
|
| Food Industry | 1 | 2011 | 2 | 0.100 |
Why?
|
| Dietary Sucrose | 1 | 2011 | 41 | 0.100 |
Why?
|
| Trans Fatty Acids | 1 | 2011 | 10 | 0.100 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2011 | 35 | 0.100 |
Why?
|
| Hyperlipidemias | 1 | 2013 | 174 | 0.090 |
Why?
|
| Depression | 1 | 2020 | 1225 | 0.090 |
Why?
|
| Ovariectomy | 3 | 2008 | 181 | 0.090 |
Why?
|
| Ion Channels | 1 | 2012 | 188 | 0.090 |
Why?
|
| Endothelium | 1 | 2011 | 71 | 0.090 |
Why?
|
| Mitochondrial Proteins | 1 | 2012 | 239 | 0.090 |
Why?
|
| Body Weight | 4 | 2016 | 999 | 0.090 |
Why?
|
| Fatty Liver | 1 | 2012 | 176 | 0.090 |
Why?
|
| Fatty Acids | 1 | 2013 | 338 | 0.090 |
Why?
|
| Mice | 7 | 2020 | 17487 | 0.090 |
Why?
|
| Stroke | 1 | 2017 | 958 | 0.080 |
Why?
|
| Interleukin-8 | 2 | 2008 | 208 | 0.080 |
Why?
|
| Lipid Metabolism | 1 | 2011 | 352 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 4 | 2020 | 4346 | 0.080 |
Why?
|
| Molecular Conformation | 2 | 2013 | 100 | 0.080 |
Why?
|
| Oxidative Stress | 2 | 2011 | 796 | 0.080 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2008 | 27 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 3526 | 0.080 |
Why?
|
| Aminoimidazole Carboxamide | 1 | 2008 | 24 | 0.080 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2008 | 63 | 0.080 |
Why?
|
| 11-beta-Hydroxysteroid Dehydrogenase Type 1 | 1 | 2008 | 1 | 0.080 |
Why?
|
| Ribonucleotides | 1 | 2008 | 36 | 0.080 |
Why?
|
| Fluorescent Dyes | 2 | 2006 | 260 | 0.070 |
Why?
|
| Behavior, Animal | 2 | 2020 | 477 | 0.070 |
Why?
|
| Protein Conformation | 3 | 2009 | 836 | 0.070 |
Why?
|
| Software Design | 1 | 2006 | 24 | 0.070 |
Why?
|
| Piperidines | 1 | 2008 | 198 | 0.070 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2008 | 165 | 0.070 |
Why?
|
| Middle Aged | 6 | 2017 | 25966 | 0.070 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 256 | 0.070 |
Why?
|
| Diffusion | 1 | 2006 | 58 | 0.070 |
Why?
|
| Lipoprotein Lipase | 2 | 2003 | 54 | 0.070 |
Why?
|
| Luminescent Measurements | 1 | 2006 | 57 | 0.070 |
Why?
|
| Brain | 1 | 2018 | 2947 | 0.070 |
Why?
|
| Proadifen | 1 | 2006 | 1 | 0.070 |
Why?
|
| Dansyl Compounds | 1 | 2006 | 3 | 0.070 |
Why?
|
| Phencyclidine | 1 | 2006 | 6 | 0.070 |
Why?
|
| Pyrazoles | 1 | 2008 | 303 | 0.060 |
Why?
|
| Calcium Channel Blockers | 1 | 2006 | 113 | 0.060 |
Why?
|
| Cell Separation | 2 | 2021 | 232 | 0.060 |
Why?
|
| Proteins | 2 | 2002 | 1038 | 0.060 |
Why?
|
| Estrogens | 1 | 2008 | 507 | 0.060 |
Why?
|
| Humans | 17 | 2021 | 123170 | 0.060 |
Why?
|
| Lipids | 1 | 2008 | 514 | 0.060 |
Why?
|
| Hypoglycemic Agents | 1 | 2008 | 423 | 0.060 |
Why?
|
| Female | 15 | 2020 | 65444 | 0.060 |
Why?
|
| Amino Acid Sequence | 2 | 2009 | 2698 | 0.060 |
Why?
|
| Body Fat Distribution | 2 | 2016 | 28 | 0.060 |
Why?
|
| Calcium Channels | 1 | 2004 | 159 | 0.060 |
Why?
|
| Flow Cytometry | 2 | 2021 | 803 | 0.060 |
Why?
|
| Case-Control Studies | 3 | 2018 | 3251 | 0.060 |
Why?
|
| Sex Factors | 3 | 2016 | 1255 | 0.050 |
Why?
|
| Catecholamines | 1 | 2003 | 56 | 0.050 |
Why?
|
| Estradiol | 2 | 2003 | 534 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 571 | 0.050 |
Why?
|
| Thermodynamics | 1 | 2002 | 141 | 0.050 |
Why?
|
| Adiponectin | 3 | 2008 | 109 | 0.050 |
Why?
|
| Family Health | 1 | 2002 | 259 | 0.050 |
Why?
|
| Growth Hormone | 1 | 2002 | 149 | 0.050 |
Why?
|
| Binding, Competitive | 1 | 2001 | 179 | 0.050 |
Why?
|
| Osmolar Concentration | 1 | 2001 | 172 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2002 | 281 | 0.050 |
Why?
|
| Pregnancy | 3 | 2019 | 7137 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2008 | 1871 | 0.040 |
Why?
|
| Adipogenesis | 1 | 2021 | 76 | 0.040 |
Why?
|
| Lysine | 1 | 2001 | 200 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 2 | 2011 | 13 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 2 | 2011 | 30 | 0.040 |
Why?
|
| Maternal Behavior | 1 | 2019 | 67 | 0.040 |
Why?
|
| Gonadal Steroid Hormones | 1 | 1999 | 83 | 0.040 |
Why?
|
| Calorimetry, Indirect | 1 | 2018 | 60 | 0.040 |
Why?
|
| Glucose Clamp Technique | 1 | 2018 | 79 | 0.040 |
Why?
|
| Down-Regulation | 2 | 2013 | 696 | 0.040 |
Why?
|
| Rats, Inbred F344 | 1 | 2018 | 102 | 0.040 |
Why?
|
| Gene Expression | 3 | 2013 | 1569 | 0.040 |
Why?
|
| Capsaicin | 1 | 2017 | 17 | 0.040 |
Why?
|
| Signal Transduction | 3 | 2018 | 4497 | 0.040 |
Why?
|
| Microfilament Proteins | 1 | 2019 | 276 | 0.040 |
Why?
|
| Adult | 6 | 2018 | 29034 | 0.040 |
Why?
|
| Young Adult | 3 | 2018 | 8865 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2012 | 867 | 0.040 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 1 | 2017 | 19 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2001 | 1390 | 0.040 |
Why?
|
| Macrophages | 1 | 2021 | 603 | 0.040 |
Why?
|
| Cytokines | 1 | 2003 | 1283 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2002 | 3048 | 0.030 |
Why?
|
| Neuroprotective Agents | 1 | 2017 | 146 | 0.030 |
Why?
|
| Osmosis | 1 | 2016 | 14 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2008 | 1682 | 0.030 |
Why?
|
| Epididymis | 1 | 2016 | 54 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2001 | 979 | 0.030 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 2008 | 136 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2016 | 204 | 0.030 |
Why?
|
| Risk Factors | 3 | 2015 | 10010 | 0.030 |
Why?
|
| Aging | 1 | 2002 | 1172 | 0.030 |
Why?
|
| Leukocytes | 1 | 2016 | 207 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2018 | 991 | 0.030 |
Why?
|
| Models, Animal | 1 | 2016 | 464 | 0.030 |
Why?
|
| Ghrelin | 1 | 2013 | 51 | 0.030 |
Why?
|
| Incretins | 1 | 2013 | 25 | 0.030 |
Why?
|
| Cell Line | 2 | 2008 | 2775 | 0.030 |
Why?
|
| Uncoupling Protein 2 | 1 | 2012 | 15 | 0.030 |
Why?
|
| Cattle | 2 | 2004 | 559 | 0.030 |
Why?
|
| RNA, Ribosomal, 18S | 1 | 2012 | 18 | 0.030 |
Why?
|
| Biomarkers | 2 | 2012 | 2942 | 0.030 |
Why?
|
| Molecular Docking Simulation | 1 | 2013 | 113 | 0.030 |
Why?
|
| Time Factors | 3 | 2011 | 6204 | 0.030 |
Why?
|
| In Vitro Techniques | 2 | 2008 | 966 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2013 | 104 | 0.030 |
Why?
|
| Aspartame | 1 | 2011 | 1 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2020 | 3715 | 0.020 |
Why?
|
| Hydrogenation | 1 | 2011 | 1 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2009 | 3871 | 0.020 |
Why?
|
| Time | 1 | 2011 | 94 | 0.020 |
Why?
|
| Homeostasis | 1 | 2016 | 684 | 0.020 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2011 | 34 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2013 | 296 | 0.020 |
Why?
|
| Beverages | 1 | 2011 | 101 | 0.020 |
Why?
|
| Soybean Oil | 1 | 2011 | 65 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2017 | 3083 | 0.020 |
Why?
|
| Milk | 1 | 2011 | 118 | 0.020 |
Why?
|
| Postmenopause | 1 | 2011 | 124 | 0.020 |
Why?
|
| Amino Acids | 1 | 2013 | 650 | 0.020 |
Why?
|
| Metabolic Diseases | 1 | 2011 | 130 | 0.020 |
Why?
|
| Mutation | 2 | 2019 | 5773 | 0.020 |
Why?
|
| Cardiovascular Diseases | 2 | 2011 | 1861 | 0.020 |
Why?
|
| Energy Intake | 1 | 2011 | 487 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 1681 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2009 | 199 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1293 | 0.020 |
Why?
|
| Enzyme Activators | 1 | 2008 | 10 | 0.020 |
Why?
|
| Overweight | 1 | 2011 | 358 | 0.020 |
Why?
|
| Glycerol | 1 | 2008 | 90 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2009 | 357 | 0.020 |
Why?
|
| Lipectomy | 1 | 2008 | 8 | 0.020 |
Why?
|
| Mammals | 1 | 2009 | 262 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 2799 | 0.020 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2012 | 387 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2008 | 159 | 0.020 |
Why?
|
| Ligands | 1 | 2008 | 533 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2008 | 809 | 0.020 |
Why?
|
| Aged | 2 | 2014 | 19067 | 0.020 |
Why?
|
| Aminoquinolines | 1 | 2004 | 35 | 0.010 |
Why?
|
| Tryptophan | 1 | 2004 | 92 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2004 | 164 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2003 | 42 | 0.010 |
Why?
|
| Isoleucine | 1 | 2003 | 27 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 6373 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 313 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2004 | 623 | 0.010 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2003 | 42 | 0.010 |
Why?
|
| Alanine | 1 | 2003 | 181 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2008 | 765 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2003 | 141 | 0.010 |
Why?
|
| Glutamine | 1 | 2003 | 195 | 0.010 |
Why?
|
| Hyperinsulinism | 1 | 2002 | 68 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 2002 | 43 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2003 | 752 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2008 | 3278 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2002 | 312 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 667 | 0.010 |
Why?
|
| Adolescent | 1 | 2013 | 19095 | 0.010 |
Why?
|
| Diet | 1 | 2002 | 1125 | 0.010 |
Why?
|
| Testosterone | 1 | 1999 | 462 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 1999 | 2533 | 0.010 |
Why?
|